The rapidly changing field of predictive biomarkers of non-small cell lung cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38953007/
Lung cancer is a leading cause of cancer-related death worldwide in both men and women, however mortality in the US and EU are recently declining in parallel with the gradual...
The review highlights the significance of identifying biomarkers in NSCLC to optimize targeted therapies, emphasizing the need for standardized testing policies and efficient use of biopsy samples for accurate diagnostics.
Radiochemotherapy in Pancreatic Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38920733/
Despite the advancements made in oncology in recent years, the treatment of pancreatic cancer remains a challenge. Five-year survival rates for this cancer do not exceed 10%. Among the reasons...
Radiotherapy, when combined with systemic treatment, holds potential to improve treatment outcomes in pancreatic cancer, especially given its current limited role compared to chemotherapy. Further research and clinical trials are needed.
Recent progress of nano-drugs in neutron capture therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38855185/
As a developing radiation treatment for tumors, neutron capture therapy (NCT) has less side effects and a higher efficacy than conventional radiation therapy. Drugs with specific isotopes are indispensable counterparts...
Neutron capture therapy (NCT) benefits from nanotechnology, enhancing drug functionality and targeting, promising less toxicity, fewer side effects, and improved biocompatibility, advancing tumor radiotherapy development.
Democratizing FLASH Radiotherapy
Source : https://pubmed.ncbi.nlm.nih.gov/38880543/
FLASH radiotherapy (RT) is emerging as a potentially revolutionary advancement in cancer treatment, offering the potential to deliver RT at ultra-high dose rates (>40 Gy/s) while significantly reducing damage to...
The democratization of FLASH radiotherapy could significantly reduce radiotherapy disparities, enabling global cancer treatment advancements through cross-disciplinary collaborations and optimized dose delivery technologies.
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors
Source : https://pubmed.ncbi.nlm.nih.gov/38598035/
Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus,...
Combining PRRT with locoregional and systemic treatments shows promise in enhancing efficacy for advanced neuroendocrine tumors, with ongoing trials exploring novel therapeutic combinations to improve patient outcomes.